NCT04430933View on ClinicalTrials.gov

A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 6, 2021

Primary Completion Date

June 30, 2022

Study Completion Date

October 30, 2022

Conditions
Advanced or Metastatic Solid TumorsNon-Small Cell Lung Cancer
Interventions
DRUG

NC318

NC318 is an experimental antibody drug that will be administered by IV infusion on the first day of each 21 day cycle

DRUG

Pemetrexed/Carboplatin

Pemetrexed/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle

DRUG

Nab paclitaxel/Carboplatin

Nab-paclitaxel/Carboplatin will be administered per the approved respective product label following the infusion of NC318 on the first day of each 21 day cycle

DRUG

Docetaxel

Docetaxel will be administered per the approved product label following the infusion of NC318 on the first day of each 21 day cycle

Sponsors

Lead Sponsor

NextCure, Inc.
All Listed Sponsors
lead

NextCure, Inc.

INDUSTRY

NCT04430933 - A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC | Biotech Hunter | Biotech Hunter